Insight Molecular Diagnostics Inc. (IMDX) Total liabilities 2020–2025
Insight Molecular Diagnostics Inc. (IMDX) total liabilities at each fiscal year-end, per SEC filings.
$57.2MFY2025 · since FY2020: $21.9M → $57.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $57.2M | +20.8% |
| FY2024 | $47.4M | -3.9% |
| FY2023 | $49.3M | -18.5% |
| FY2022 | $60.5M | -35.9% |
| FY2021 | $94.3M | +330.1% |
| FY2020 | $21.9M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More IMDX financial trends
IMDX RevenueIMDX Net incomeIMDX Net marginIMDX Gross profitIMDX Gross marginIMDX Operating incomeIMDX Operating marginIMDX Operating cash flowIMDX Free cash flowIMDX Capital expendituresIMDX Return on equityIMDX Stock buybacksIMDX Dividends paidIMDX Total assetsIMDX Shareholders’ equityIMDX overview →